U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Pleural Malignant Mesothelioma

MedGen UID:
1686266
•Concept ID:
C5206948
•
Neoplastic Process

Definition

Pleural malignant mesothelioma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Pleural Malignant Mesothelioma

Professional guidelines

PubMed

Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT, Egbune C
Cancer Treat Res 2023;185:79-89. doi: 10.1007/978-3-031-27156-4_5. PMID: 37306905
Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.
Favoni RE, Daga A, Malatesta P, Florio T
Br J Pharmacol 2012 May;166(2):532-53. doi: 10.1111/j.1476-5381.2012.01873.x. PMID: 22289125Free PMC Article
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
Fizazi K, John WJ, Vogelzang NJ
Semin Oncol 2002 Feb;29(1):77-81. doi: 10.1053/sonc.2002.30233. PMID: 11836672

Recent clinical studies

Etiology

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
Darabi S, Braxton DR, Xiu J, Carneiro BA, Swensen J, Antonarakis ES, Liu SV, McKay RR, Spetzler D, El-Deiry WS, Demeure MJ
Medicina (Kaunas) 2022 Dec 10;58(12) doi: 10.3390/medicina58121818. PMID: 36557020Free PMC Article
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, Scherpereel A, Koczywas M, Forster M, Cameron RB, Peikert T, Argon EK, Michaud NR, Szanto A, Yang J, Chen Y, Kansra V, Agarwal S, Fennell DA
Lancet Oncol 2022 Jun;23(6):758-767. Epub 2022 May 16 doi: 10.1016/S1470-2045(22)00277-7. PMID: 35588752
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Expression of Numb and Gli1 in malignant pleural mesothelioma and their clinical significance.
Zhang C, Kang Y, Ma R, Chen F, Chen F, Dong X
J Cancer Res Ther 2018 Jul-Sep;14(5):970-976. doi: 10.4103/0973-1482.180614. PMID: 30197333
Human epidemiology: a review of fiber type and characteristics in the development of malignant and nonmalignant disease.
Merchant JA
Environ Health Perspect 1990 Aug;88:287-93. doi: 10.1289/ehp.9088287. PMID: 2272325Free PMC Article

Diagnosis

Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT, Egbune C
Cancer Treat Res 2023;185:79-89. doi: 10.1007/978-3-031-27156-4_5. PMID: 37306905
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL
Mol Ther 2019 Nov 6;27(11):1919-1929. Epub 2019 Jul 30 doi: 10.1016/j.ymthe.2019.07.015. PMID: 31420241Free PMC Article
Expression of Numb and Gli1 in malignant pleural mesothelioma and their clinical significance.
Zhang C, Kang Y, Ma R, Chen F, Chen F, Dong X
J Cancer Res Ther 2018 Jul-Sep;14(5):970-976. doi: 10.4103/0973-1482.180614. PMID: 30197333
Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
Truini A, Coco S, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Barletta G, Biello F, Maggioni C, Grossi F
Microrna 2016;5(1):12-18. doi: 10.2174/2211536605666160128151018. PMID: 26817512
Antiangiogenic therapies for malignant pleural mesothelioma.
Yano S, Li Q, Wang W, Yamada T, Takeuchi S, Nakataki E, Ogino H, Goto H, Nishioka Y, Sone S
Front Biosci (Landmark Ed) 2011 Jan 1;16(2):740-8. doi: 10.2741/3716. PMID: 21196199

Therapy

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Zauderer MG, Szlosarek PW, Le Moulec S, Popat S, Taylor P, Planchard D, Scherpereel A, Koczywas M, Forster M, Cameron RB, Peikert T, Argon EK, Michaud NR, Szanto A, Yang J, Chen Y, Kansra V, Agarwal S, Fennell DA
Lancet Oncol 2022 Jun;23(6):758-767. Epub 2022 May 16 doi: 10.1016/S1470-2045(22)00277-7. PMID: 35588752
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL
Mol Ther 2019 Nov 6;27(11):1919-1929. Epub 2019 Jul 30 doi: 10.1016/j.ymthe.2019.07.015. PMID: 31420241Free PMC Article
Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?".
Di Noia V, Vita E, Ferrara M, Strippoli A, Basso M, Schinzari G, Cassano A, Bria E, Barone C, D'Argento E
Curr Treat Options Oncol 2019 Feb 21;20(3):23. doi: 10.1007/s11864-019-0616-7. PMID: 30790063
Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
Truini A, Coco S, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Barletta G, Biello F, Maggioni C, Grossi F
Microrna 2016;5(1):12-18. doi: 10.2174/2211536605666160128151018. PMID: 26817512

Prognosis

Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT, Egbune C
Cancer Treat Res 2023;185:79-89. doi: 10.1007/978-3-031-27156-4_5. PMID: 37306905
Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress.
Perrino M, De Vincenzo F, Cordua N, Borea F, Aliprandi M, Santoro A, Zucali PA
Front Immunol 2023;14:1121557. Epub 2023 Jan 27 doi: 10.3389/fimmu.2023.1121557. PMID: 36776840Free PMC Article
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma.
Truini A, Coco S, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Barletta G, Biello F, Maggioni C, Grossi F
Microrna 2016;5(1):12-18. doi: 10.2174/2211536605666160128151018. PMID: 26817512

Clinical prediction guides

Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress.
Perrino M, De Vincenzo F, Cordua N, Borea F, Aliprandi M, Santoro A, Zucali PA
Front Immunol 2023;14:1121557. Epub 2023 Jan 27 doi: 10.3389/fimmu.2023.1121557. PMID: 36776840Free PMC Article
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS
J Clin Oncol 2022 Feb 20;40(6):681-692. Epub 2022 Jan 5 doi: 10.1200/JCO.21.01567. PMID: 34985934Free PMC Article
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N
Lancet Oncol 2020 Jan;21(1):121-133. Epub 2019 Dec 4 doi: 10.1016/S1470-2045(19)30671-0. PMID: 31812554
Use of Immune Checkpoint Inhibitors in Mesothelioma.
Forde PM, Scherpereel A, Tsao AS
Curr Treat Options Oncol 2019 Feb 14;20(2):18. doi: 10.1007/s11864-019-0613-x. PMID: 30762130
Molecular pathogenesis of malignant mesothelioma.
Sekido Y
Carcinogenesis 2013 Jul;34(7):1413-9. Epub 2013 May 14 doi: 10.1093/carcin/bgt166. PMID: 23677068

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...